This brief outlines governance considerations related to vendor risk allocation, contractual
protections, and insurance alignment when adopting AI- or LLM-enabled clinical tools.
Purpose
While AI-assisted systems may influence documentation or clinical reasoning, liability exposure is
often retained by the provider organization. Boards should ensure contractual and insurance
structures reflect this reality before implementation.
1. Understand Where Liability Resides
In most AI vendor agreements:
- The vendor disclaims responsibility for clinical decision-making
- Liability is limited to contract value or a capped amount
- Clinical outcomes are excluded from indemnification
Even when tools materially influence clinical workflows, responsibility typically remains with:
The licensed clinician
The employing organization
Boards must understand that technological influence does not equal liability transfer.
2. Contractual Risk Allocation
Before adoption, boards should request review of:
- Limitation-of-liability clauses
- Indemnification language
- Warranty disclaimers
- Error or performance guarantees
- Service level agreements (SLAs)
Key questions include: - Does the vendor assume responsibility for transcription errors?
- Are there remedies for systemic model failure?
- Is there indemnification for regulatory enforcement tied to system defects?
Risk allocation language often determines exposure more than marketing claims.
3. Model Updates and Version Drift
AI systems evolve.
Boards should ensure that contracts address:
- Notification of model updates
- Re-validation requirements after major version changes
- Audit rights related to performance claims
- Data usage rights for model retraining
Uncontrolled model updates may alter system behavior without governance review.
Oversight must extend beyond initial deployment.
4. Data Ownership and Secondary Use
Boards should confirm clarity regarding:
- Ownership of Clinical Data
- Vendor rights to use encounter data for model training
- De-identification standards
- Cross-border data processing
- Termination rights and data return policies
Data governance intersects directly with institutional reputation and regulatory compliance.
5. Insurance Alignment
Boards should request confirmation that:
- Professional liability carriers are informed of AI system integration
- Coverage extends to AI-assisted workflows
- Cyber liability policies address third-party AI vendors
- Risk assessments are updated to reflect technology integration
Failure to align insurance coverage with operational reality creates blind exposure.
6. Regulatory and Enforcement Risk
AI-enabled systems may introduce:
- Documentation anomalies
- Coding pattern shifts
- Prescribing pattern deviations
- Decision-support bias
Boards should ensure internal compliance monitoring considers AI influence in:
Audit design
Billing review
Quality oversight
Incident reporting
Regulators evaluate outcomes, not vendor marketing language.
7. Escalation and Termination Controls
Organizations should define:
- Conditions under which AI systems may be suspended
- Escalation triggers tied to error thresholds
- Governance authority to pause deployment
- Contractual exit provisions
Technology adoption should not outpace the organization’s ability to intervene.
8. Strategic Framing
AI-enabled tools can offer:
- Documentation efficiency
- Standardization of workflows
- Clinical decision support
- Compliance monitoring enhancements
These advantages are meaningful.
However, vendor risk allocation often reflects a different reality:
Vendors provide capability.
Providers retain accountability.
Boards that align contracts, insurance coverage, and internal controls before deployment reduce
downstream exposure.
Closing Observation
Technology vendors rarely assume clinical liability.
Organizations must assume that responsibility remains internal unless contractually transferred.
AI adoption is not simply a technical decision.
It is a governance decision involving contractual structure, insurance alignment, and oversight
design.
Clear allocation of responsibility protects patients, clinicians, and institutional stability.
Boards evaluating AI-enabled clinical tools may benefit from an independent governance
perspective prior to deployment.
A structured external review often surfaces gaps that are easy to miss during implementation
planning.
© 2026 J A Epperson Analysis and Advisory, Ltd. All Rights Reserved.